IL84852A - Molecular cloning and expression of human IL-3 - Google Patents

Molecular cloning and expression of human IL-3

Info

Publication number: IL84852A
Authority: IL; Israel
Prior art keywords: human; pgb; protein; obtainable; dna
Prior art date: 1986-12-16

Application number

IL8485287A

Other languages

English (en)

Other versions

IL84852A0 (en

Original Assignee

Gist Brocades Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-12-16

Filing date

1987-12-16

Publication date

1994-06-24

1987-12-16 Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv

1988-06-30 Publication of IL84852A0 publication Critical patent/IL84852A0/xx

1994-06-24 Publication of IL84852A publication Critical patent/IL84852A/en

Links

101001033279 Homo sapiens Interleukin-3 Proteins 0.000 title claims abstract description 103
230000014509 gene expression Effects 0.000 title claims abstract description 45
102000055276 human IL3 Human genes 0.000 title claims description 71
238000010369 molecular cloning Methods 0.000 title description 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 134
102000004169 proteins and genes Human genes 0.000 claims abstract description 114
239000002299 complementary DNA Substances 0.000 claims abstract description 73
108010002386 Interleukin-3 Proteins 0.000 claims description 49
238000000034 method Methods 0.000 claims description 48
108020004414 DNA Proteins 0.000 claims description 37
230000000694 effects Effects 0.000 claims description 29
108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
239000013604 expression vector Substances 0.000 claims description 22
239000002773 nucleotide Substances 0.000 claims description 22
125000003729 nucleotide group Chemical group 0.000 claims description 22
150000001413 amino acids Chemical class 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 17
241000894006 Bacteria Species 0.000 claims description 14
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
102000004139 alpha-Amylases Human genes 0.000 claims description 10
108090000637 alpha-Amylases Proteins 0.000 claims description 10
229940024171 alpha-amylase Drugs 0.000 claims description 10
241000193830 Bacillus <bacterium> Species 0.000 claims description 8
241000894007 species Species 0.000 claims description 8
238000013518 transcription Methods 0.000 claims description 8
230000035897 transcription Effects 0.000 claims description 8
230000001105 regulatory effect Effects 0.000 claims description 6
241000233866 Fungi Species 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
239000000523 sample Substances 0.000 claims description 5
108091092195 Intron Proteins 0.000 claims description 4
241000235070 Saccharomyces Species 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
108091036066 Three prime untranslated region Proteins 0.000 claims description 3
238000012216 screening Methods 0.000 claims description 3
230000002103 transcriptional effect Effects 0.000 claims description 3
230000000977 initiatory effect Effects 0.000 claims description 2
235000015097 nutrients Nutrition 0.000 claims description 2
241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 claims 1
238000003259 recombinant expression Methods 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 9
101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 abstract description 4
239000012535 impurity Substances 0.000 abstract description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 100
210000004027 cell Anatomy 0.000 description 67
239000013612 plasmid Substances 0.000 description 67
102000000646 Interleukin-3 Human genes 0.000 description 46
239000012634 fragment Substances 0.000 description 39
208000031261 Acute myeloid leukaemia Diseases 0.000 description 27
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 27
238000010276 construction Methods 0.000 description 27
108010076504 Protein Sorting Signals Proteins 0.000 description 26
241000588724 Escherichia coli Species 0.000 description 25
102000037865 fusion proteins Human genes 0.000 description 24
108020001507 fusion proteins Proteins 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 21
239000003636 conditioned culture medium Substances 0.000 description 21
108091026890 Coding region Proteins 0.000 description 17
238000003556 assay Methods 0.000 description 16
239000013598 vector Substances 0.000 description 15
101150066555 lacZ gene Proteins 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
230000004071 biological effect Effects 0.000 description 13
239000002609 medium Substances 0.000 description 13
108010059881 Lactase Proteins 0.000 description 12
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
108010005774 beta-Galactosidase Proteins 0.000 description 12
102100026189 Beta-galactosidase Human genes 0.000 description 11
238000010367 cloning Methods 0.000 description 11
230000002607 hemopoietic effect Effects 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
229940116108 lactase Drugs 0.000 description 11
239000000047 product Substances 0.000 description 11
230000035755 proliferation Effects 0.000 description 11
241001138401 Kluyveromyces lactis Species 0.000 description 10
241001529936 Murinae Species 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 10
239000008188 pellet Substances 0.000 description 10
125000003275 alpha amino acid group Chemical group 0.000 description 9
210000000130 stem cell Anatomy 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
239000006228 supernatant Substances 0.000 description 9
235000014469 Bacillus subtilis Nutrition 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical group C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 8
239000000499 gel Substances 0.000 description 8
241000194108 Bacillus licheniformis Species 0.000 description 7
230000005757 colony formation Effects 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
239000000203 mixture Substances 0.000 description 7
230000035772 mutation Effects 0.000 description 7
229920002401 polyacrylamide Polymers 0.000 description 7
230000009466 transformation Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
238000001516 cell proliferation assay Methods 0.000 description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
230000029087 digestion Effects 0.000 description 6
230000004927 fusion Effects 0.000 description 6
210000003714 granulocyte Anatomy 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
230000006820 DNA synthesis Effects 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
238000001514 detection method Methods 0.000 description 5
239000013613 expression plasmid Substances 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
238000002955 isolation Methods 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
239000002243 precursor Substances 0.000 description 5
230000010076 replication Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
230000014616 translation Effects 0.000 description 5
238000001262 western blot Methods 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108700039691 Genetic Promoter Regions Proteins 0.000 description 4
108700007698 Genetic Terminator Regions Proteins 0.000 description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
108091092724 Noncoding DNA Proteins 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
230000000925 erythroid effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000006166 lysate Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
238000013519 translation Methods 0.000 description 4
BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 3
102000007469 Actins Human genes 0.000 description 3
108010085238 Actins Proteins 0.000 description 3
102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
241000388186 Deltapapillomavirus 4 Species 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 3
241000235649 Kluyveromyces Species 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
210000002960 bfu-e Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000011132 hemopoiesis Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
210000003643 myeloid progenitor cell Anatomy 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
241000228212 Aspergillus Species 0.000 description 2
108010077805 Bacterial Proteins Proteins 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
108090000204 Dipeptidase 1 Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
101150068888 MET3 gene Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
101100109292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-13 gene Proteins 0.000 description 2
101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
206010033661 Pancytopenia Diseases 0.000 description 2
102000002508 Peptide Elongation Factors Human genes 0.000 description 2
108010068204 Peptide Elongation Factors Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000003969 blast cell Anatomy 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000002791 cfu-m Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000012411 cloning technique Methods 0.000 description 2
208000024389 cytopenia Diseases 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000000751 eop Anatomy 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
101150106093 gpt gene Proteins 0.000 description 2
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
210000004524 haematopoietic cell Anatomy 0.000 description 2
210000001357 hemopoietic progenitor cell Anatomy 0.000 description 2
101150069378 hil-3 gene Proteins 0.000 description 2
102000057308 human HGF Human genes 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000010354 integration Effects 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000035800 maturation Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
210000000287 oocyte Anatomy 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000012846 protein folding Effects 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000004448 titration Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
JUSMHIGDXPKSID-PHYPRBDBSA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-sulfanyloxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](S)[C@H](O)[C@@H](O)[C@H]1O JUSMHIGDXPKSID-PHYPRBDBSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
BHTBAVZSZCQZPT-GUBZILKMSA-N Ala-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N BHTBAVZSZCQZPT-GUBZILKMSA-N 0.000 description 1
206010005089 Blast cell proliferation Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000702374 Enterobacteria phage fd Species 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108010058643 Fungal Proteins Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101100340751 Homo sapiens IL3 gene Proteins 0.000 description 1
241000282620 Hylobates sp. Species 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
244000199866 Lactobacillus casei Species 0.000 description 1
235000013958 Lactobacillus casei Nutrition 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710135670 Putative Xaa-Pro dipeptidyl-peptidase Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108010039445 Stem Cell Factor Proteins 0.000 description 1
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
101710143531 Xaa-Pro dipeptidyl-peptidase Proteins 0.000 description 1
241000269368 Xenopus laevis Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
108010087924 alanylproline Proteins 0.000 description 1
150000001447 alkali salts Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000011712 cell development Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
238000007821 culture assay Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
150000002256 galaktoses Chemical class 0.000 description 1
201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
210000001501 megacaryocyte Anatomy 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
231100001160 nonlethal Toxicity 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
108010064037 prorennin Proteins 0.000 description 1
230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
230000005029 transcription elongation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
239000007160 ty medium Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL8485287A 1986-12-16 1987-12-16 Molecular cloning and expression of human IL-3 IL84852A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP86202285		1986-12-16
EP87201322		1987-07-13

Publications (2)

Publication Number	Publication Date
IL84852A0 IL84852A0 (en)	1988-06-30
IL84852A true IL84852A (en)	1994-06-24

Family

ID=26103432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8485287A IL84852A (en)	1986-12-16	1987-12-16	Molecular cloning and expression of human IL-3

Country Status (14)

Country	Link
JP (2)	JPH01502157A (fi)
AT (1)	ATE161882T1 (fi)
AU (1)	AU617095B2 (fi)
CA (1)	CA1341503C (fi)
DE (1)	DE3752158T2 (fi)
ES (1)	ES2113338T3 (fi)
FI (1)	FI102293B1 (fi)
GR (1)	GR3025857T3 (fi)
IE (1)	IE81129B1 (fi)
IL (1)	IL84852A (fi)
NO (1)	NO180544C (fi)
NZ (1)	NZ222939A (fi)
PT (1)	PT86381B (fi)
WO (1)	WO1988004691A1 (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR871029B (en) *	1986-07-14	1987-11-02	Genetics Inst	Novel osteoinductive factors
US6238889B1 (en)	1986-12-16	2001-05-29	Dsm N.V.	Molecular cloning and expression of the Pro8 isoform of human IL-3
OA09736A (en) *	1987-02-18	1993-11-30	Schering Biotech Corp	"Human interleukin-3 and muteins thereof".
US5304637A (en) *	1987-07-13	1994-04-19	Gist-Brocades N.V.	Expression and purification of human interleukin-3 and muteins thereof
GB2210883B (en) *	1987-10-08	1992-01-02	British Bio Technology	Synthetic interleukin-3 gene
US6384194B1 (en)	1987-12-16	2002-05-07	Dsm N.V.	Expression and purification of human interleukin-3 and muteins thereof
AU3864089A (en) *	1988-07-20	1990-02-19	Immunex Corporation	Nonglycosylated human interleukin-3 compositions
NZ232913A (en) *	1989-03-15	1992-08-26	Gist Brocades Nv	Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
US5128450A (en) *	1989-06-30	1992-07-07	Urdal David L	Nonglycosylated human interleukin-3 analog proteins
DK0413383T3 (da)	1989-08-14	1997-07-07	Gist Brocades Nv	Mutanter af humant interleukin-3.
US5516512A (en)	1989-08-14	1996-05-14	Gist-Brocades, N.V.	N- and C-terminal truncation and deletion mutants of human interleukin-3
DK0596881T3 (da) *	1991-08-01	1997-10-13	Fond Nat Transfusion Sanguine	Ekspression i ikke-tumurale humane lymofoblastoider med en integrativ vektor
US5738849A (en) *	1992-11-24	1998-04-14	G. D. Searle & Co.	Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
ATE251669T1 (de) *	1992-11-24	2003-10-15	Searle & Co	Mutierte polypeptide des interleukin-3(il-3)
US5501962A (en) *	1993-06-21	1996-03-26	G. D. Searle & Co.	Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US6017523A (en) *	1995-06-06	2000-01-25	G.D. Searle & Co.	Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
WO1999041382A2 (en) *	1998-02-17	1999-08-19	Hyseq, Inc.	A novel interleukin-3 and uses thereof
WO2006079169A1 (en) *	2005-01-25	2006-08-03	Apollo Life Sciences Limited	Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
JP2009532061A (ja) *	2006-04-03	2009-09-10	ニユー・イングランド・バイオレイブス・インコーポレイテツド	組換えウシ血清アルブミン（ｒＢＳＡ）の発現、分泌及び精製、並びにその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4695542A (en) *	1983-10-04	1987-09-22	Dnax Research Institute Of Molecular And Cellular Biology, Inc.	cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
AU570762B2 (en) *	1983-12-23	1988-03-24	Australian National University, The	Cloning of cdna for il-3
GR871029B (en) *	1986-07-14	1987-11-02	Genetics Inst	Novel osteoinductive factors

1987
- 1987-12-16 IL IL8485287A patent/IL84852A/en not_active IP Right Cessation
- 1987-12-16 PT PT86381A patent/PT86381B/pt not_active IP Right Cessation
- 1987-12-16 WO PCT/NL1987/000037 patent/WO1988004691A1/en active IP Right Grant
- 1987-12-16 JP JP63500606A patent/JPH01502157A/ja active Pending
- 1987-12-16 DE DE3752158T patent/DE3752158T2/de not_active Expired - Fee Related
- 1987-12-16 ES ES87202566T patent/ES2113338T3/es not_active Expired - Lifetime
- 1987-12-16 AU AU10577/88A patent/AU617095B2/en not_active Ceased
- 1987-12-16 IE IE340987A patent/IE81129B1/en not_active IP Right Cessation
- 1987-12-16 AT AT87202566T patent/ATE161882T1/de not_active IP Right Cessation
- 1987-12-16 NZ NZ222939A patent/NZ222939A/en unknown
1988
- 1988-08-08 FI FI883688A patent/FI102293B1/fi not_active IP Right Cessation
- 1988-08-12 NO NO883614A patent/NO180544C/no not_active IP Right Cessation
1997
- 1997-05-28 JP JP9154513A patent/JPH1080286A/ja active Pending
- 1997-12-16 CA CA000554561A patent/CA1341503C/en not_active Expired - Fee Related
1998
- 1998-01-08 GR GR980400027T patent/GR3025857T3/el unknown

Also Published As

Publication number	Publication date
ATE161882T1 (de)	1998-01-15
IL84852A0 (en)	1988-06-30
GR3025857T3 (en)	1998-04-30
NO180544C (no)	1997-05-07
AU617095B2 (en)	1991-11-21
DE3752158T2 (de)	1998-05-20
FI102293B (fi)	1998-11-13
ES2113338T3 (es)	1998-05-01
FI883688A0 (fi)	1988-08-08
CA1341503C (en)	2006-04-04
NO180544B (no)	1997-01-27
FI102293B1 (fi)	1998-11-13
NO883614D0 (no)	1988-08-12
PT86381B (pt)	1990-11-20
NO883614L (no)	1988-08-12
WO1988004691A1 (en)	1988-06-30
NZ222939A (en)	1991-03-26
AU1057788A (en)	1988-07-15
JPH1080286A (ja)	1998-03-31
IE81129B1 (en)	2000-03-22
PT86381A (en)	1988-01-01
DE3752158D1 (de)	1998-02-12
JPH01502157A (ja)	1989-08-03
FI883688A (fi)	1988-08-08
IE873409L (en)	1988-06-12

Publication	Publication Date	Title
IL84852A (en)	1994-06-24	Molecular cloning and expression of human IL-3
EP0275598B1 (en)	1998-01-07	Molecular cloning and expression of human IL-3
US5081228A (en)	1992-01-14	Interleukin-1 receptors
US5319071A (en)	1994-06-07	Soluble interleukin-1 receptors
EP0318296B1 (en)	1998-08-19	DNA encoding proteins which bind to human IL-1
CA1341611C (en)	2011-04-12	Interleukin-1 receptors
JP2952203B2 (ja)	1999-09-20	タンパク質の製造方法
US4965195A (en)	1990-10-23	Interleukin-7
FI106044B (fi)	2000-11-15	Menetelmä nisäkkään interleukiini-4-reseptorin (IL-4R) ja sen vasta-aineen tuottamiseksi ja IL-4R:ä koodaava DNA, vektori ja isäntäsolu
IE890207L (en)	1989-07-25	Amphiregulin: a novel bifunctional growth modulating glycoprotein
US5115096A (en)	1992-05-19	Amphiregulin: a bifunctional growth modulating glycoprotein
JP2749838B2 (ja)	1998-05-13	インターロイキン−７
Sherr et al.	1990	Colony-stimulating factor 1 (macrophage colony-stimulating-factor)
IE912135A1 (en)	1992-01-01	Mast cell growth factor
US5296592A (en)	1994-03-22	Process for purifying interleukin-1 receptors
US5304637A (en)	1994-04-19	Expression and purification of human interleukin-3 and muteins thereof
US5328988A (en)	1994-07-12	Interleukin-7
US6384194B1 (en)	2002-05-07	Expression and purification of human interleukin-3 and muteins thereof
AU625534B2 (en)	1992-07-16	Interleukin-1 receptors
US6238889B1 (en)	2001-05-29	Molecular cloning and expression of the Pro8 isoform of human IL-3
DD296691A5 (de)	1991-12-12	Verfahren zur herstellung von antikoerpern gegen ein epitop von amphiregulin

Legal Events

Date	Code	Title
1998-04-05	KB	Patent renewed
1998-12-06	RH	Patent void
1999-03-12	HP	Change in proprietorship
2002-02-10	KB	Patent renewed
2006-09-05	MM9K	Patent not in force due to non-payment of renewal fees